Multiple myeloma (MM) incidence is markedly higher in blacks compared with whites, which may be related to a higher prevalence of monoclonal gammopathy of undetermined significance (MGUS). Our objective was to define the prevalence and risk factors of MGUS in a large cohort representative of the US population. Stored serum samples from the National Health and Nutritional Examination Survey (NHANES) III or NHANES 1999 -2004 were available for 12 482 individuals of age X50 years (2331 'blacks', 2475 Hispanics, 7051 'whites' and 625 'others') on which agarose-gel electrophoresis, serum protein immunofixation, serum-free light-chain assay and M-protein typing were performed. MGUS was identified in 365 participants (2.4%). Adjusted prevalence of MGUS was significantly higher (Po0.001) in blacks (3.7%) compared with whites (2.3%) (P ¼ 0.001) or Hispanics (1.8%), as were characteristics that posed a greater risk of progression to MM. The adjusted prevalence of MGUS was 3.1% and 2.1% for the North/ Midwest versus South/West regions of the United States, respectively (P ¼ 0.052). MGUS is significantly more common in blacks, and more often has features associated with higher risk of progression to MM. A strong geographic disparity in the prevalence of MGUS between the North/Midwest versus the South/West regions of the United States was found, which has etiologic implications.
INTRODUCTION
Multiple myeloma (MM) is a fatal B-cell dysplasia characterized by plasma cell infiltration in the bone marrow and monoclonal immunoglobulin (M-protein) in serum, urine or both.
1,2 MM is almost always preceded by the premalignant state, monoclonal gammopathy of undetermined significance (MGUS), 3, 4 which is characterized by the presence of an M-protein without evidence of MM or related disorder. 5 MGUS is associated with a relentless risk of progression to MM or related malignancy at a rate of 1% per year. 6 The risk is higher in those with high-risk biomarkers. Patients with an abnormal serum-free light-chain ratio, non-IgG MGUS and a high-serum M-protein level (X1.5 g/dl) have a 58% absolute risk of developing MM over a 20-year period. 7 There is marked racial disparity in the incidence of MM. 8 African Americans have a twofold or greater risk for MM compared with whites. 9 The higher incidence of MM in blacks may result from a higher prevalence of the precursor lesion, MGUS, or an increased risk of progression of MGUS to MM. 10, 11 So far, accurate estimates of the prevalence of MGUS in blacks and whites from a representative sample of the entire US population are not available. As MM is a devastating malignancy, a better understanding of the reasons for the racial disparity in incidence is of critical importance.
The largest population-based study of MGUS so far comes from the relatively homogenous white population living in Olmsted County, Minnesota, where the prevalence of MGUS was estimated at 3.2% of the population X50 years of age, but data are needed on the prevalence of MGUS in blacks and Hispanics, as well as in whites from other regions of the US. Further, data on risk factors associated with the occurrence of MGUS across the racial groups are required in order to determine optimal screening and preventive strategies. In this study, we utilized samples and data from the National Health and Nutritional Examination Survey (NHANES), a nationally representative sample of the US population, to answer these important questions. We used sensitive laboratory techniques to determine the prevalence of MGUS and studied the association of MGUS with baseline variables collected through NHANES.
MATERIALS AND METHODS

Study population and serum samples
The data for this paper come from NHANES III (1988) (1989) (1990) (1991) (1992) (1993) (1994) and NHANES (1999) (2000) (2001) (2002) (2003) (2004) , which are population-based cross-sectional surveys consisting of in-person home interviews and medical examinations conducted by the Centers for Disease Control and Prevention (CDC) to assess the health and nutritional status of adults and children in the United States. 13, 14 Participant identification is based on a stratified multistage complex sample design to select a nationally representative sample of the civilian, non-institutionalized US population, with oversampling (higher sampling rates) of older adults and non-Hispanic blacks and Mexican Americans, and other groups. Survey data, including demographics, health status, health disorders, behaviors and so on, are collected through household interviews. Physical examinations and blood collection are carried out at a mobile examination center by phlebotomists.
Testing for monoclonal proteins
Testing for the presence of MGUS was performed at the Protein Immunology Laboratory, Mayo Clinic, Rochester, MN, USA, using laboratory techniques that have been well described previously. 7, 12 Briefly, conventional agarose-gel electrophoresis was performed on sera from all subjects. Samples with an equivocal or definite M-protein present on electrophoresis were then subjected to serum protein immunofixation, and to serum-free light-chain assay for confirmation and typing of the M-protein. All testing and interpretation was done by individuals blinded to all demographic and other details pertaining to the samples being tested.
Prevalence estimates and risk factors
Once testing was completed, data were transferred to the National Center for Health Statistics for linking to the NHANES Public Use files that contain the serologic and demographic data needed for these analyses. Once the MGUS data were released to the public on the NHANES web site, the data could be analyzed by the National Cancer Institute. The prevalence of MGUS was estimated in the total population, as well as for whites, blacks and Mexican Americans separately, and by age, gender and other known risk factors.
Statistical analysis
Prevalence rates were calculated by dividing the weighted number of persons with MGUS from the sample by the weighted number of total persons (with or without MGUS). Adjusted prevalence rates were computed from logistic regression analysis where confounders such as age, gender and smoking were included in the models. 15 Wald F-tests, which take account of the complex design of NHANES, were used to test hypotheses regarding the estimated prevalence of MGUS. Restricted cubic spline regression in logistic regression analyses was used to examine MGUS prevalence for age by gender, race/ethnicity groups and geographic region. 15, 16 Age-adjusted prevalence rates, directly standardizing to the US age distribution in 2000, were compared with similarly adjusted rates reported in the predominantly white Olmsted County study. 12 Risk factors for MGUS were studied using available survey information (including medical exams, routine blood tests, questionnaires concerning medical history, nutrition and demographics) available from NHANES. We first conducted risk factor analyses involving a predefined set of variables that, based on prior studies, have been suggested as having potential associations with MGUS-namely, body mass index (BMI), [17] [18] [19] [20] socioeconomic status (SES), 17, [21] [22] [23] immunostimulatory factors,(17-21) smoking, vitamin D 24, 25 and pesticide exposure. 26, 27 We explored the role of SES by using an educational and poverty index ratio as proxy markers. Subsequently, we performed exploratory analyses looking for new risk factors associated with MGUS and with racial disparity. All analyses were conducted using SAS version 9.2 (SAS Institute, Cary, NC, USA) and SUDAAN version 10.0.1 (Research Triangle Institute, Research Triangle Park, NC, USA) software programs. All analyses accounted for the sample weighting and complex sample design of the NHANES, as well as correction for nonresponse. All hypothesis tests were determined significant for two-sided P-values o0.05.
RESULTS
Prevalence
Of 13 278 adults of age X50 years enrolled in NHANES III or NHANES (1999) (2000) (2001) (2002) (2003) (2004) , stored serum samples to test for monoclonal proteins were available for 12 482 persons (2331 nonHispanic blacks considered 'black', 2475 Mexican Americans, 7051 non-Hispanic whites considered 'white' and 625 'others'). MGUS confirmed on serum immunofixation was identified in 365 participants, for an overall prevalence of 2.4% (95% confidence interval (CI), 2.0-2.7) ( Table 1) . MGUS was detected in 144 of 6413 sampled women, as compared with 221 of 6069 sampled men, and prevalence rates were higher (P ¼ 0.011) in men (2.8%; 95% CI, 2.4-3.3) than in women (2.0%; 95% CI, 1.6-2.5). The unweighted median age among MGUS for both sexes was 71.8 years. From fitted restricted cubic spline regression, the prevalence of MGUS increased with advancing age in both sexes; beyond 60 years of age, however, men consistently had higher prevalence rates than women ( Figure 1a ).
Of the 365 cases of MGUS for which race or ethnic group was known, 90 participants were black (25%), 214 were white (58%) and 52 were Mexican American (14%). The adjusted prevalence rate was significantly higher (Po0.001) in blacks (3.7%) compared with whites (2.3%) (P ¼ 0.001) or Hispanics (1.8%) ( Table 1) . For all races, the prevalence of MGUS increased with advancing age, but blacks displayed consistently higher prevalence rates. The spline model shown in Figure 1b suggests an earlier age of onset for blacks, as well as a relatively similar prevalence between whites and Mexican Americans before age 70. Table 2 contrasts the NHANES prevalence rates among whites with the reported prevalence from the predominantly white population of Olmsted County. 12 The weighted NHANES prevalence of MGUS in whites was significantly lower (Po0.05) compared with Olmsted County (2.3% versus 3.2%, respectively). After directly standardizing all prevalence rates to the 2000 US population, the Olmsted County rates among patients over 50 years of age (4.0% in men and 2.7% in women) were still greater than the NHANES-weighted results (2.8% in men and 2.0% in women). Consequently, we further examined MGUS prevalence by region of the country in the NHANES III sample because region is not publicly available in NHANES 1999-2004. The unadjusted prevalence combining the North and Midwest regions was 3.1% (95% CI, 2.2-4.0%) versus 2.1% (95% CI, 1.4-2.7%) in the combined Table) . We also evaluated rheumatoid arthritis in relation to MGUS prevalence in order to explore the plausible role of immune dysregulation; our results show no statistical increased prevalence of MGUS in persons with arthritis or with a history of arthritis (P ¼ 0.57) ( Table 3 ). An additional exploratory analysis to determine other associated factors such as C-reactive protein and vitamin D did not reveal any significant associations (Supplementary Table) . Likewise, neither smoking nor dichlorodiphenyldichloroethylene, a major metabolite of dichlorodiphenyltrichloroethane, was associated with an increased prevalence of MGUS (Supplementary Table) . A nonsignificant association of MGUS with higher education and lower poverty income ratio (Table 3 ) was observed for blacks and for Mexican Americans, but not for whites.
Laboratory characteristics of MGUS
The laboratory characteristics of the MGUS detected in this study are shown in Table 4 ; these factors have a direct impact on the risk and type of progression. The IgM immunoglobulin isotype was less common in blacks compared with whites (3% versus 15%, respectively), although the numbers are small. Conversely, the median monoclonal protein concentration was higher in black participants (0.83 g/dl (95% CI, 0.66-1.00)) compared with whites (0.70 g/dl (95% CI, 0.69-0.79)). However, the range of individual M-protein values was wider in whites (unmeasurable À 3.3 g/dl) compared with blacks (unmeasurable À 2.9 g/dl). IgA MGUS was more common in Mexican Americans (Table 3) .
DISCUSSION
MM is significantly more common in blacks, 9 possibly related to a higher prevalence of MGUS, the precursor premalignant stage of MM, in blacks. However, data on the prevalence of MGUS in populations with substantial racial diversity are sparse and irresolute. 10, 11 In the present study, which represents the first and largest screening study of MGUS with available risk factor data, we were able to include B12 400 adults X50 years old to accurately quantify the prevalence of MGUS by race and ethnicity in a stratified random sampling of the entire US population. We demonstrate that the prevalence of MGUS is indeed significantly higher in blacks compared with whites. Moreover, this study estimates the prevalence of MGUS in Mexican Americans for the first time; our results show prevalence rates in Mexican Americans that are slightly lower than, but overall relatively similar to, those of whites.
Not only did blacks have a higher overall prevalence of MGUS but also the excess continued to increase with advancing age. This rendered the elderly black population above 80 years of age with a prevalence of 8.6%, a rate nearly double that of whites of the same age. Across all age groups, the prevalence of MGUS in blacks was similar to that seen in whites and Mexican Americans a decade older. These results suggest racial heterogeneity early in the carcinogenic disease pathway, while also consistent with the younger age distribution seen among blacks compared with whites in MM.
In addition to a higher prevalence, MGUS in the black population was also more likely to have features associated with a greater risk of progression to MM or related disorder. 7 Thus, compared with whites, blacks and Mexican Americans had a strikingly lower rate of IgM MGUS, which progresses primarily to Waldenströ m's macroglobulinemia and rarely transforms to MM. 
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These results are consistent with other studies showing lower rates of IgM MGUS in blacks and are in accordance with the racial composition of Waldenströ m's macroglobulinemia. 28 Contrary to prior investigations, 28 blacks also had higher M-protein levels, a known risk factor for progression to MM, compared with whites and Hispanics. The result is that blacks not only are more likely to have MGUS but are also probably at greater risk of progression with M proteins that are larger and with greater racial disparity in the non-IgG type. Molecular analyses are warranted in order to further elucidate the disparity of cytogenetic subtypes among the races and to evaluate possible differences in prognosis and progression within racial and ethnic groups. Moreover, this disparity may affect counseling efforts.
Our previous studies suggest that racial disparities in MGUS may be related more to genetic rather than environmental differences. For example, we showed that the increased prevalence of MGUS in African Americans is also seen in blacks from Ghana, Africa. 29 Moreover, when women of similar SES were studied, the prevalence of MGUS was twice as high in African Americans compared with whites. 17 As the increased prevalence Abbreviation: CI, confidence interval.
of MGUS in blacks appeared to be independent of other confounding factors, including markers for health and disease status such as smoking and SES, environmental factors are less likely to account for these effects. Another major finding of our study is that the prevalence of MGUS in whites across the US population is significantly lower than the rates previously reported for Olmsted County, where 694 of the 21 463 enumerated residents (99% white) had MGUS. Comparably age-and sex-adjusted, the prevalence of MGUS in the current study was 2.4% overall (2.3% in whites) versus the prevalence of 3.2% reported in Olmsted County residents. 12 However, we get closer agreement with Olmsted County for the prevalence of MGUS as estimated from the combined North and Midwest regions of NHANES III, where the prevalence was 3.1% but drops to 2.1% for the South and West regions from the NHANES III. Furthermore, the death rate from MM is much higher in Minnesota than in most other regions of the country. 30 Because MM is a highly fatal disease, these deaths are probably a reasonable indicator of MM incidence, and, because MM is almost always preceded by MGUS, this suggests that the regional discrepancies in MGUS prevalence that we have observed are real. The underlying causes of these striking geographical variations in the prevalence of MGUS among US whites need to be investigated in future studies as they may provide etiologic clues based on environmental exposures and ethnic differences in North and Midwest populations compared with the South and West regions of the US.
Uniquely, we were also able to analyze data from the NHANES Survey Research Program in order to investigate the association of MGUS with numerous potential risk factors. Male gender and advancing age were independently associated with a higher prevalence of MGUS, consistent with previous studies. 28 The finding of increased prevalence with age has implications for screening, follow-up and attribution of associations in elderly patients. On further analysis, there was a trend to a higher risk of MGUS with increasing BMI (Table 3) . Smaller studies [17] [18] [19] [20] have associated obesity with an excess risk of MGUS and MM, and the present study provides supporting evidence for this association. [17] [18] [19] [20] However, our attempt to explain this association by assessing mechanistic associations with factors such as C-peptide, insulin or glucose levels did not reveal additional correlations. Our data provide some support to prior studies that have suggested an association between low SES and MGUS. 17, [21] [22] [23] Previous registrybased studies have also suggested immune-mediated conditions, such as rheumatoid arthritis, as possible correlates of MGUS and MM, 31-34 but we were unable to confirm this. In this comprehensive screening study, we provide the basis for the increased risk of MM in blacks by demonstrating an unequivocal increase in the prevalence of the precursor lesion MGUS and by showing that the type of MGUS in blacks carries a higher risk of progression. We also find a strong geographic disparity in the prevalence of MGUS between the North/Midwest versus the South/West regions of the US, a finding that has etiologic implications. Advancing age, male sex, increasing BMI and low SES were associated with a trend to increased risk of MGUS across all racial/ethnic groups. These findings have implications for prognosis, counseling and public health policy. Our study design utilizing the NHANES allows for our results and conclusions to be wholly representative of the US population.
